A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) Clinical Trial

Official title:

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04240002
• Other study ID #: 2215-CL-0603
• Secondary ID: 2018-002301-61
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 4, 2020
• Est. completion date: July 31, 2031

Study information

• Verified date: April 2024
• Source: Astellas Pharma Inc
• Contact: Astellas Pharma Global Development
• Phone: 800-888-7704
• Email: Astellas.registration[@]astellas.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of the phase 2 portion (dose expansion) is to determine complete remission (CR) rates and composite complete remission (CRc) rates after two cycles of therapy. The study will also assess safety, tolerability and toxicities of gilteritinib in combination with FLAG, evaluate FLT3 inhibition, assess pharmacokinetics (PK), perform serial measurements of minimal residual disease, obtain preliminary estimates of 1-year event free survival (EFS) and overall survival (OS) rate and assess the acceptability as well as palatability of the formulation. One cycle is defined as 28 days of treatment. A participant completing 1 or 2 treatment cycles in phase 1 or 2 will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 97
• Est. completion date: July 31, 2031
• Est. primary completion date: August 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 21 Years

Eligibility

Inclusion Criteria:

• Subject is aged = 6 months and < 21 years of age* at the time of signing informed consent and/or assent, as applicable.
• *For phase 2: Enrollment of subjects from 6 months to less than 1 year and 1 year to less than 2 years will be dependent on the establishment of recommended phase 2 dose (RP2D) in the respective age groups during phase 1.
• Subject has a diagnosis of acute myeloid leukemia (AML) according to The French-American-British (FAB) classification with = 5% blasts in the bone marrow, with or without extramedullary disease (except subjects with active central nervous system [CNS] leukemia).
• In the phase 1 portion of the study, subject must be in first or greater relapse or refractory to induction therapy with no more than 1 attempt at remission induction (up to 2 induction cycles).
• For the phase 2 portion of the study, subject must be in refractory to or at the first hematologic relapse after first-line remission induction AML therapy (up to 2 induction cycles).
• Subject has fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
• Myelosuppressive chemotherapy:
• For subject who relapses while receiving cytotoxic therapy, at least 21 days must have elapsed since the completion of cytotoxic therapy and prior to screening, unless the subject has recovered earlier than 21 days.
• Cytoreduction with the following can be initiated and continued for up to 24 hours prior to the start of systemic protocol therapy (cycle 1 day -1).
• hydroxyurea,
• low dose cytarabine (100 mg/m^2 per dose once daily for 5 days) or
• other low dose/maintenance therapies as per local site practice.
• Subject who has received other FLT3 inhibitors (e.g., lestaurtinib, sorafenib, etc) is eligible for this study.
• Hematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor and prior to screening.
• Biologic (anti-neoplastic agent): at least 7 days must have elapsed since the completion of therapy with a biologic agent and prior to screening. For agents that have known adverse events (AEs) occurring beyond 7 days after administration, this period must be extended beyond the time during which AEs are known to occur.
• X-ray treatment (XRT):
• 14 days must have elapsed for local palliative XRT for CNS chloromas and prior to screening; no washout period is necessary for other chloromas;
• Prior to screening, 90 days must have elapsed if the subject had a prior traumatic brain injury or has received craniospinal XRT.
• For subject undergoing hematopoietic stem cell transplant (HSCT), at least 90 days must have elapsed since HSCT and subject must not have active graft-versus-host disease (GVHD).
• Subject has Karnofsky score = 50 (if the subject is of = 16 years of age) or Lansky score of = 50 (if the subject is < 16 years of age). A score < 50 is acceptable if related to the subject's leukemia.
• Subject must meet the following criteria as indicated on the clinical laboratory tests.
• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x upper limit normal (ULN) for age
• Total serum bilirubin = 1.5 x ULN for age
• Estimated glomerular filtration rate of > 60 mL/min/1.73 m^2.
• A female subject is eligible to participate if she is not pregnant and at least 1 of

the following conditions applies:

• Not a woman of childbearing potential (WOCBP) OR
• WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at Screening, and throughout the study period and for 60 days after the final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study, and for 180 days after the final study drug administration.
• A male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 180 days after the final study drug administration.
• A male subject must not donate sperm during the treatment period and for at least 120 days after the final study drug administration.
• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 180 days after the final study drug administration.
• Subject and subject's parent(s) or legal guardian agrees not to participate in another interventional study while on treatment.
• Live Vaccines - At least 6 weeks must have elapsed since the administration of the last dose of a live vaccine and prior to the initiation of study treatment (cycle 1, day -1)
• Phase 1: Subject is positive for FLT3 (ITD and/or tyrosine kinase domain [TKD]) mutation in bone marrow or blood as determined by the local institution.
• Phase 2: Subject is positive for the FLT3 (ITD) mutation in bone marrow or blood as determined by the local institution.

Exclusion Criteria:

• Subject has active CNS leukemia.
• Subject has uncontrolled or significant cardiovascular disease, including:
• Diagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes (TdP)); any history of arrhythmia will be discussed with the sponsor prior to subject's entry into the study
• Prolonged Fridericia's Correction Formula (QTcF) interval on pre-entry electrocardiogram (ECG) (= 450 ms)
• Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)
• Heart rate < 50 beats/minute on pre-entry ECG
• Uncontrolled hypertension
• Complete left bundle branch block
• Subject has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The subject needs to be off pressors and have negative blood cultures for 48 hours.
• Subject is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
• Subject has active clinically significant GVHD or is on treatment with immunosuppressive drugs for treatment of active GVHD, with the exception of subjects being weaned from systemic corticosteroids where the subject is receiving = 0.5 mg/kg of prednisone (or equivalent) daily dose for prior GVHD. Subject has received calcineurin inhibitors within 4 weeks prior to screening, unless used as GVHD prophylaxis.
• Subject has active malignant tumors other than AML.
• Subject has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance; interfere with consent, study participation, follow-up or interpretation of study results.
• Subject has hypokalemia and/or hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]). Repletion of potassium and magnesium levels during the screening period is allowed.
• Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A/P-glycoprotein (P-gp).
• Subject is known to have human immunodeficiency virus infection.
• Subject has active hepatitis B or C, or other active hepatic disorder.
• Subjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.
• Subjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.
• Subjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA is undetectable.
• Subject must wait for at least 5 half-lives after stopping therapy with any investigational agent and before starting gilteritinib.
• Subject has a known or suspected hypersensitivity to gilteritinib, cytarabine, fludarabine, granulocyte colony-stimulating factor (G-CSF) or any components of the formulation used.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia (AML)
• Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• gilteritinib
Administered orally.
• fludarabine
Administered by intravenous (IV) infusion
• cytarabine
Administered by intravenous (IV) infusion
• granulocyte colony-stimulating factor (G-CSF)
Administered by subcutaneous injection

Locations

Country	Name	City	State
Canada	Site CA15001	Montreal	Quebec
France	Site FR33003	Bordeaux
France	Site FR33004	Marseille cedex 05
France	Site FR33005	Paris
France	Site FR33006	Paris
France	Site FR33002	Vandoeuvre-Lès-Nancy
Germany	Site DE49004	Essen	Nordrhein-Westfalen
Germany	Site DE49002	Freiburg	Baden-Württemberg
Germany	Site DE49001	Halle (Saale)	Sachsen-Anhalt
Germany	Site DE49003	Regensburg	Bayern
Italy	Site IT39003	Bologna
Italy	Site IT39002	Monza
Italy	SIte IT39001	Roma
Spain	Site ES34001	Barcelona
Spain	Site ES34002	Barcelona
Spain	Site ES34003	Sevilla
United Kingdom	Site GB44001	Birmingham
United Kingdom	Site GB44006	Bristol
United Kingdom	Site GB44005	Cardiff
United Kingdom	Site GB44003	Glasgow
United Kingdom	Site UK44007	Sutton
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	The Children's Hospital of Philadelphia (CHOP)	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Italy,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with dose limiting toxicity (DLT) (phase 1/dose escalation)	DLT is defined as any of the events meeting the DLT criteria that occur during DLT observation period & that is considered to be possibly or probably related to protocol therapy. Nonhematologic (NH) DLT will be defined as grade 3 NH toxicity at least possibly related to protocol therapy that persists for >48 hours without resolution to grade = 2 or 4 NH toxicity, regardless of duration, at least possibly related to protocol therapy. Hy's law or treatment-related deaths will be considered as a DLT. Gilteritinib dosing will be interrupted if NH DLT occurs. Exceptions include toxicities commonly seen with intensive AML reinduction regimens. Hematologic DLT will be defined as failure to recover a peripheral absolute neutrophil count (ANC) >500/µL & non-transfusion dependent platelet count >20000/µL due to documented bone marrow aplasia/hypoplasia at day 42 from start of cycle 1 day 1. Failure to recover peripheral counts due to disease involvement of bone marrow will not be considered DLT	Up to 28 days
Primary	Complete Remission (CR) rate after 2 cycles of therapy (phase 2)	CR rate is defined as the number of participants who achieve the best response of CR divided by the number of participants in the analysis population. Complete remission is defined as having bone marrow regenerating normal hematopoietic cells and achieving a morphologic leukemia-free state and must have an absolute neutrophil count (ANC) = 1 x 10^9/L and platelet count = 100 x 10^9/L and normal marrow differential with < 5% blasts, and they will be red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia.	Up to 56 days
Primary	Composite complete remission (CRc) rate after 2 cycles of therapy (phase 2)	CRc rate is defined as the number of participants who achieve the best response of CRc (CR, CRp,or CRi) divided by the number of participants in the analysis population. Complete remission with incomplete platelet recovery (CRp) is defined as achieving CR except for incomplete platelet recovery (< 100 x 10^9/L) at a post baseline visit. Complete remission with incomplete hematologic recovery (CRi) is defined as achieving CR except for incomplete hematological recovery with residual neutropenia < 1 x 10^9/L with or without complete platelet recovery at a post baseline visit. Red blood cell (RBC) and platelet transfusion independence is not required.	Up to 56 days
Secondary	Number of participants with Adverse Events (AEs)	An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.	Up to 2 years plus 28 day follow up
Secondary	Number of participants with vital sign abnormalities and /or adverse events (AEs)	Number of participants with potentially clinically significant vital sign values.	Up to 2 years
Secondary	Number of participants with laboratory value abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant laboratory values.	Up to 2 years
Secondary	Number of participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant ECG values.	Up to 2 years
Secondary	Percentage of inhibition of phosphorylated FLT3 in participants.	Inhibition of FLT3 phosphorylation after drug treatment will be determined relative to pre-treatment phosphorylated FLT3 levels in participants to assess the relationship with gilteritinib dose. Phosphorylated FLT3 will be measured by plasma inhibitory activity (PIA) assay.	Up to 49 days
Secondary	Pharmacokinetics (PK) of gilteritinib: oral clearance (CL/F)	CL/F will be reported from the PK plasma samples collected.	Up to 45 days
Secondary	PK of gilteritinib: apparent volume of distribution (Vd/F)	Vd/F will be reported from the PK plasma samples collected.	Up to 45 days
Secondary	PK of gilteritinib: Maximum Concentration (Cmax)	Cmax will be reported from the PK plasma samples collected.	Up to 45 days
Secondary	PK of gilteritinib: Time of Maximum Concentration (tmax)	tmax will be reported from the PK plasma samples collected.	Up to 45 days
Secondary	PK of gilteritinib: Area Under the Concentration (AUC)	AUC will be reported from the PK plasma samples collected.	Up to 45 days
Secondary	Duration of Event Free Survival (EFS)	EFS is defined as the time from the date of enrollment until the date of documented relapse (excluding relapse after PR), treatment failure or death, whichever occurs first. If a participant experiences relapse or death, the participant is defined as having EFS event related to either "relapse" or "death", and the event date is the date of relapse or death. If a participant fails to achieve any of the response of CR, CRp, CRi or PR during the treatment period, the participant is defined as having EFS event related to treatment failure, and the event date is the enrollment date. For a participant who is not known to have had a relapse or treatment failure or death event, EFS is censored at the date of last relapse-free disease assessment. Participant is not censored at hematopoietic stem cell transplant (HSCT).	Up to 2 years
Secondary	Duration of Overall survival (OS)	OS is defined as the time from the date of enrollment until the date of death from any cause. For a participant who is not known to have died by the end-of-study follow-up, OS is censored at the date of last contact.	Up to 4 years and 2 months
Secondary	The number of participants with negative minimal residual disease (MRD) status	MRD negative status will be defined as FLT3-internal tandem duplication (ITD) signal ratio = 10^-4.	Up to 2 years
Secondary	Number of participants with MRD negative status in relation to CR rate	MRD negative status will be defined as FLT3-internal tandem duplication (ITD) signal ratio = 10^-4.	Up to 2 years
Secondary	Number of participants with MRD negative status in relation to CRc rate	MRD negative status will be defined as FLT3-internal tandem duplication (ITD) signal ratio = 10^-4.	Up to 2 years
Secondary	Number of participants with MRD negative status in relation to Overall survival (OS)	MRD negative status will be defined as FLT3-internal tandem duplication (ITD) signal ratio = 10^-4.	Up to 2 years
Secondary	Clinical Outcome Assessment of Taste	The acceptability and palatability of gilteritinib oral formulation as assessed by the participant using a single scale. The 5 point facial hedonic scale has high to low as: Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much.	Up to 57 days